Rosen Law Firm Urges Brainstorm Cell Therapeutics Inc. Investors with Losses to Act Before Deadline

In a significant development for investors, Rosen Law Firm, a preeminent global investor rights law firm, has issued a reminder to shareholders who acquired Brainstorm Cell Therapeutics Inc. BCLI securities between August 15, 2022, and September 27, 2023. These investors are urged to ensure they have legal counsel before the fast-approaching January 2, 2024 deadline, which has been set for the lead plaintiff in the securities class action initiated by the firm.

Why It's Important

Investors who purchased BCLI securities during the specified Class Period may have a right to recompense without any out-of-pocket fees or costs due to a contingency fee arrangement. With the deadline looming, the firm encourages investors to take action to be a part of the class action suit against Brainstorm Cell Therapeutics Inc.

Next Steps for Investors

If you wish to join the lawsuit, you are advised to visit Rosen Law Firm's website or get in touch with attorneys Phillip Kim, Esq. through either toll-free phone calls or email. Note that the case has already been filed, and to serve as a lead plaintiff—an essential role that involves representing the class of investors—you must make your move no later than January 2, 2024. Until a class is certified, you are not represented by counsel unless you retain one, but you may still choose counsel of your preference or remain an absent class member.

The Credibility of Rosen Law Firm

Rosen Law Firm has a reputation for ensuring investors choose qualified counsel with a successful track record. Their practice is focused on representing global investors in securities class actions and shareholder derivative litigation. The firm boasts a notable history of securing significant settlements for investors and providing top-notch legal expertise in finance and investment-related litigations. They emphasize their achievement in 2017, where they ranked first for the number of securities class action settlements, establishing their position as a leading firm in the domain.

Details of the Allegations

The lawsuit claims that defendants made false and misleading statements regarding Brainstorm Cell Therapeutics Inc., and failed to disclose pertinent information, thereby harming investors. The allegations include downplaying the gravity of the FDA's refusal to file letter and continuing to obscure risks relating to the submission of their biologics license application (BLA). Consequently, the firm maintains that investor losses were the direct result of these actions when the truth was revealed to the market.

Brainstorm Cell Therapeutics Inc. is a biotechnology company headquartered in New York that specializes in the development of autologous cell therapies aimed at neurodegenerative diseases. As the situation unfolds, legal representation and further action may be imperative for affected investors of BCLI.

Rosen, Law, Securities, Deadline, ClassAction, Investors, BrainstormCell, Therapeutics, BCLI, Counsel, Compensation